Bruce Bostrom

Dr. Bruce Bostrom


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2011 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
MPMahati Pidaparti
Mahati Pidaparti
BBBruce Bostrom
Bruce Bostrom

1 October 2013 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
BBBruce Bostrom
Bruce Bostrom
PUPriya Ba Uppal
Priya Ba Uppal
JCJulie Chu
Julie Chu
YMYoav Messinger
Yoav Messinger
LGLaura Gandrud
Laura Gandrud
RMRobert McEvoy
Robert McEvoy
Background: Hyperglycemia during corticosteroid and asparaginase therapy for acute lymphoblastic leukemia is a significant side effect that is usually treated with insulin. Metformin is an oral antidiabetic biguanide that may cause metabolic acidosis and liver enzyme abnormalities of possible concern in patients receiving chemotherapy. Procedure: We reviewed patients with acute lymphoblastic leukemia treated with corticosteroids and asparaginase who received metformin for control of hyperglycemia. Results: Seventeen patients received metformin, including 4 who received insulin before starting metformin therapy. Twelve were treated during initial induction therapy and 5 during relapse reinduction. Corticosteroids included dexamethasone in 11, prednisone in 5, and megesterol in 1. Fifteen received pegasparaginase. Patients were treated with metformin for a median of 6 days (range, 2 to 46 d). Metformin was started at a median glucose level of 286 mg/dL (range, 112 to 499 mg/mL). The glucose level was controlled with metformin alone in 12 patients without the need for insulin. Four patients received insulin before or concomitantly with metformin. In 1 patient, metformin failed to control the glucose level, and insulin was administered. No significant toxicity from metformin was seen. Two patients had an elevated anion gap and creatinine level because of extreme hyperglycemia. One patient had mild elevation in total bilirubin and 5 patients had mild elevation in serum alanine aminotransferase levels. There were no episodes of hypoglycemia. Conclusions: Metformin is safe and effective for therapy-induced hyperglycemia. Initially, insulin may be required for significant hyperglycemia or metabolic abnormalities. We are unaware of any prior studies using metformin in this population.

1 January 2007 in Journal of Pediatric Oncology Nursing
Verified
Journal Article
Closed access
MHMary C. Hooke
Mary C. Hooke
EGErin Grund
Erin Grund
HQHeather Quammen
Heather Quammen
BMBlaine Miller
Blaine Miller
PMPaul McCormick
Paul McCormick
BBBruce Bostrom
Bruce Bostrom
This article describes the use and effectiveness of adjuvant propofol for pain control for pediatric oncology patients at the end of life. All patients experienced severe pain and agitation, not well controlled by continuous infusion opioids and benzodiazepines. Upon starting propofol, most patients had a temporary stabilization in the dose of opioids with subjective improvement in pain control, increased alertness, and improved ability to interact. Propofol infusions were continued until death in most patients. Two patients received propofol infusions at home. Subsequent increases in opioids in 6 patients and propofol in all patients were required for optimal pain control. Adverse effects included agitation in 5 patients and hallucinations in 2, which were controllable with benzodiazepines. One patient developed severe tetany, requiring propofol interruption; propofol was successfully restarted at a lower dose with an adjuvant benzodiazepine. The authors conclude that propofol is a useful and tolerable adjuvant agent for pain management in pediatric oncology patients at the end of life. It is a useful adjuvant if pain is unresponsive to continuous infusion opioids or if rapidly escalating doses of opioids are required.

10 January 2014 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
SMSamyuktha Melachuri
Samyuktha Melachuri
LGLaura Gandrud
Laura Gandrud
BBBruce Bostrom
Bruce Bostrom

4 March 2021 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
RKRuchika Kamojjala
Ruchika Kamojjala
BBBruce Bostrom
Bruce Bostrom
Mercaptopurine (6MP) is used to treat acute lymphoblastic leukemia (ALL) and is metabolized by hypoxanthine guanine phosphoribosal transferase to form 6-thioguanine nucleotide (6TGN). It is also metabolized by thiopurine methyl-transferase to produce 6-methylmercaptopurine (6MMP). Elevated levels of 6MMP have been associated with toxic effects that may interfere with therapy. Allopurinol is known to inhibit thiopurine methyl-transferase which reduces red cell 6MMP and increases 6TGN. Allopurinol has been utilized successfully in adult and pediatric patients with inflammatory bowel disease who have experienced 6MMP related gastrointestinal toxicity. Between August 2015 and August 2018 we started 25 patients with ALL in maintenance on allopurinol in combination with a reduced dose of 6MP. They all had unacceptable side-effects from elevated 6MMP, including abdominal pain, nausea, vomiting, decreased appetite, hypoglycemia, fatigue, and liver toxicity. In addition many had a facial rash. All patients showed resolution of symptoms within a few weeks after starting allopurinol. The red cell levels of 6MMP rapidly declined in the first month. The red cell levels of 6TGN transiently increased in spite of the lower 6MP dose. There was no decrease in absolute neutrophil count or hemoglobin. Platelets decreased slightly not requiring therapy modification. Elevated bilirubin normalized, and alanine aminotransferase decreased significantly with most normalizing. All patients continued on allopurinol with reduced dose 6MP until completing therapy. Allopurinol, in conjunction with a reduced dose of 6MP, effectively resolves 6MMP related side-effects in ALL patients on maintenance chemotherapy. This approach may lead to increased adherence to oral 6MP during ALL maintenance in patients with 6MMP induced side-effects.

1 January 1997 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PDF file
PGPaul S. Gaynon
Paul S. Gaynon
MCMya Lisa Crotty
Mya Lisa Crotty
HSHarland N. Sather
Harland N. Sather
BBBruce Bostrom
Bruce Bostrom
JNJames B. Nachman
James B. Nachman
Fatih M. UckunFatih M. Uckun
Fatih M. Uckun
We used reverse transcriptase polymerase chain reaction (RT-PCR) assays to examine primary leukemic cells in on-study diagnostic bone marrow specimens from 642 children with newly diagnosed acute lymphoblastic leukemia (ALL) for the expression of MLL-AF4, E2APBX1, and BCR-ABL fusion transcripts. All PCR assays were performed centrally in the Children's Cancer Group ALL Biology Reference Laboratory. MLL-AF4 transcript was found in only 0.7% of the study population which excluded infants. E2A-PBX1 transcript was found in 2.5% of the study population and 3.3% of B-precursor cases. Expression was associated with massive hepatomegaly. BCR-ABL transcript was found in 2.3% of cases and correlated with older age, induction failure, and inferior event-free survival (EFS). RT-PCR assays allow rapid identification of patients with MLL-AF4 and BCR-ABL positive ALL. These patients have a poor outcome with contemporary therapy and rapid identification facilitates timely allocation to innovative treatment programs.